Biography
Terry Rauch, Ph.D., is the Director of Research and Development in the Policy and Oversight Office of the Assistant Secretary of Defense, US Department of Defense. Dr. Rauch has over 35 years of experience in many facets of the Military Health System and has held numerous senior level positions in the Army and the Office of the Secretary of Defense. As a senior military officer he served as the Chief of Staff to the Assistant Secretary of Defense for Health Affairs, and served as principal advisor to four Assistant Secretaries of Defense for Health Affairs on matters pertaining to biomedical research, development and acquisition as well as medical products and devices needed to protect U.S. military forces against Chemical, Biological, Radiological and Nuclear threats.
Research Interest
Psychology, Public Health, Neurosciences, Biomedical Research, Military Health System
Biography
WILLIAM F. PEACOCK, IV, MD, FACEP, graduated Wayne State University and completed his Emergency Medicine training at William Beaumont Hospital, in Detroit, Michigan. Currently a professor of Emergency Medicine at the Baylor College of Medicine in Houston, Texas, he also serves as the Emergency Medicine Associate Chair and Research Director. Dr. Peacock is the immediate past President and the current Chief Medical Officer of the Society of Chest Pain Centers and Providers, and is an active international speaker at cardiology and emergency medicine meetings. With over 250 publications in heart failure and acute coronary syndromes, he also is the co-editor of several books on Cardiac Emergencies, Short Stay Management of Heart Failure, and Short Stay Management of Chest Pain. Finally, he is the 2004 and 2010 winner of the Best Research Paper award from the American College of Emergency Physicians, and is the Codman Award recipient from the American Association of Group Practice.
Research Interest
Clinical interests and research focus include acute coronary syndrome, acute heart failure, biomarkers, improvements in emergency medical care and more rapid patient disposition.
Biography
Dr. Wellington obtained her PhD at the University of British Columbia and performed postdoctoral fellowships at Harvard Medical School, the University of Calgary, and the University of British Columbia. She joined the Department of Pathology and Laboratory Medicine at the University of British Columbia in 2000 and was promoted to Professor in 2011. Dr. Wellington’s research program encompasses the genetic and environmental risk factors that affect dementia, including apolipoprotein E metabolism, history of traumatic brain injury (TBI), and cerebrovascular dysfunction. Her current research projects include drug discovery efforts to increase apolipoprotein function in the brain for application to both Alzheimer’s Disease and TBI, understanding the relationships between TBI and dementia, and innovative tissue engineering approaches to investigate cerebrovascular function in health and disease. Dr. Wellington’s niche expertise affords her a truly unique perspective. She is a highly sought-after speaker who has given well over 100 presentations in the last five years to both scientific and lay audiences and an active member of a wide range of multidisciplinary teams, committees, and grant review panels. She has served on the Editorial Board for the Journal of Lipid Research, and has demonstrated strong leadership in heading a team from the Canadian Consortium on Neurodegeneration of Aging. Dr. Wellington has published 95 peer-reviewed articles and 24 invited reviews. Her work has been cited over 6,000 times, as reflected by her h-factor of 43 (SCOPUS). In addition to her impressive body of research, Dr. Wellington is an enthusiastic mentor, and is actively engaged in service to the UBC community. She has supervised 38 research trainees, and founded a UBC Collaborative Grant Workshop Program that provides post-doctoral fellows with advanced skills in grant writing and reviewing.
Research Interest
Since joining UBC in 2000, my career has been focused on Alzheimer’s Disease (AD), which is the most common form of dementia in the elderly and defined by the presence of amyloid plaques and neurofibrillary tangles in the diseased brain. ApoE is the major apolipoprotein expressed in the brain and the best-established genetic risk factor for late onset AD. Using genetic and pharmacological approaches, we have shown that the amount of fats carried on apoE regulates the removal of Abeta peptides, which are neurotoxic species that accumulate as amyloid in the AD brain. This initial work has now grown to include several integrated research programs in my laboratory, all of which converge on understanding the risk factors for dementia and developing effective preventative or therapeutic strategies for this devastating condition.